Surface Oncology News

Surface Oncology (SURF) Was Downgraded to a Hold Rating at JonesTrading

TipRanksJun 20, 2023 16:15 ET

Wedbush Downgrades Surface Oncology to Neutral From Outperform, Adjusts Price Target to $1.15 From $3

MT NewswiresJun 20, 2023 11:10 ET

Analysts Conflicted on These Healthcare Names: Calliditas Therapeutics (CALT), Surface Oncology (SURF) and Crinetics Pharmaceuticals (CRNX)

TipRanksJun 20, 2023 06:20 ET

HC Wainwright & Co. Downgrades Surface Oncology to Neutral, Announces $5 Price Target

BenzingaJun 20, 2023 06:09 ET

Analysts Offer Insights on Healthcare Companies: NanoString Tech (NSTG), Aclaris Therapeutics (ACRS) and Surface Oncology (SURF)

TipRanksMay 8, 2023 12:16 ET

HC Wainwright & Co. Reiterates Buy on Surface Oncology, Maintains $6 Price Target

BenzingaMay 5, 2023 08:24 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Ultragenyx Pharmaceutical (RARE) and Surface Oncology (SURF)

TipRanksMay 5, 2023 07:41 ET

Surface Oncology (SURF) Gets a Buy From H.C. Wainwright

TipRanksMay 5, 2023 06:31 ET

Surface Oncology (SURF) Gets a Buy From Wedbush

TipRanksMar 10, 2023 11:27 ET

HC Wainwright & Co. Reiterates Buy on Surface Oncology, Maintains $6 Price Target

BenzingaMar 10, 2023 06:58 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Akebia Therapeutics (AKBA), Clearside Biomedical (CLSD) and Surface Oncology (SURF)

TipRanksMar 10, 2023 06:33 ET

JonesTrading Remains a Buy on Surface Oncology (SURF)

TipRanksMar 9, 2023 14:07 ET

Humana To Rally Over 14%? Here Are 5 Other Price Target Changes For Thursday

Benzinga Real-time NewsNov 3, 2022 08:05 ET

Wedbush Cuts Price Target on Surface Oncology to $3 From $12, Citing New Clinical Data, Updated Pipeline Focus; Outperform Rating Kept

MT NewswiresNov 3, 2022 07:37 ET

H.C. Wainwright Keeps Their Buy Rating on Surface Oncology (SURF)

TipRanksNov 3, 2022 06:40 ET

Surface Oncology Analyst Ratings

Benzinga Analyst RatingsNov 3, 2022 06:18 ET

HC Wainwright & Co. Maintains Buy on Surface Oncology, Lowers Price Target to $6

Benzinga Real-time NewsNov 3, 2022 06:18 ET

Analysts' Top Healthcare Picks: LivaNova (LIVN), Surface Oncology (SURF)

TipRanksNov 2, 2022 13:05 ET

Analysts Offer Insights on Healthcare Companies: and Surface Oncology (SURF)

TipRanksSep 7, 2022 05:30 ET

Surface Oncology Price Target Cut to $8.50/Share From $10.00 by HC Wainwright & Co.

Dow JonesAug 8, 2022 06:56 ET